(EASE) Evaluation of EfficAcy and Safety of Xolair (Omalizumab) in IgE mediated Asthma.

Trial Profile

(EASE) Evaluation of EfficAcy and Safety of Xolair (Omalizumab) in IgE mediated Asthma.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Acronyms EASE
  • Sponsors Novartis
  • Most Recent Events

    • 11 Sep 2013 Interim subgroup results based on baseline immunoglobulin E (IgE) presented at the 23rd Annual Congress of the European Respiratory Society.
    • 11 Sep 2013 Interim results for weeks 16 and 28 presented at the 23rd Annual Congress of the European Respiratory Society.
    • 19 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top